AZ receives BARDA funding for COVID-19 vaccine

Andrew Cummings
May 24, 2020

The nation has invested more than $41 million to clinical trials at Oxford University. For example, Johnson & Johnson received $456 million from the federal government to scale up production of its vaccine candidate to 300 million doses, with the first doses of the vaccine expected by early 2021 if FDA signs off.

"The vaccine has to work and that's one question, and the other question is, even if it works we have to be able to demonstrate it". In the clinical trial, six monkeys were administered the vaccine and three monkeys were injected with ChAdOx1 GFP.

An initial trial that started on April 23 has already seen more than 1,000 volunteers aged 18-55 receive the injection and Oxford said phases II and III will add people aged 56 and older as well as children of 5 to 12 years.

Oxford University's Jenner Institute and the Oxford Vaccine Group began development on a coronavirus vaccine in January, using a virus taken from chimpanzees.

British researchers testing an experimental vaccine against the new coronavirus are moving into advanced studies and aim to immunise more than 10,000 people to determine if the shot works.

Clinical trials to test Oxford University's new vaccine for Covid-19 are "progressing very well", the head of the Oxford Vaccine Group (OVG) said on Friday.

He told the Telegraph: "It's a race against the virus disappearing, and against time".

It is one of only four major vaccine trials now taking place worldwide, though over 100 experimental vaccines are known to be in development.

At the moment, there's a 50 percent chance that we get no result at all.

Leading virologist Shahid Jameel said India's vaccine manufacturing capacity is quite remarkable and at least three Indian companies - Serum Institute, Bharat Biotech and Biologicals E are at the forefont, working with worldwide partners to manufacture a vaccine for COVID-19.

Adam Finn, honorary consultant at Bristol Royal Hospital for Children, professor of paediatrics at the University of Bristol and director of the Bristol Children's Vaccine Centre at Bristol Medical School, said: "We are delighted to be supporting our colleagues in Oxford by collaborating on this extremely important study".

The effectiveness of the vaccine is still to be determined.

"But there will still be a long way to go from there until an approved active substance becomes available in large quantities for the global population".

They say that's because the number of people with the virus in the United Kingdom is falling too quickly.

This trial phase will help researchers understand how the vaccine produces an immune response in bodies of different age groups.

The World Health Organization (WHO) listed eight vaccines candidates as being tested on humans in a May 15 overview.

Other reports by iNewsToday